

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,235,232 B2
APPLICATION NO. : 10/615723
DATED : June 26, 2007
INVENTOR(S) : Zoon et al.

Page 1 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 16, Line 23, "SDM1 as" should be --SDM1as--.

Column 16, Line 30, "SDM2 as" should be --SDM2as--.

Column 16, Line 36, "SDM3 as" should be --SDM3as--.

Column 16, Line 42, "SDM4 as" should be --SDM4as--.

Column 17, Line 35, "the manufactures" should be --the manufacturers--.

Column 17, Line 40, "IFNA-b 2" should be --IFNA2--.

Column 18, Lines 6-7, "purification of may" should be --purification may--.

Column 18, Line 25, "1997)" should be --1997).--.

Column 18, Line 63, "Bethesda Md." should be --Bethesda, MD.--.

Column 20, Line 2, "with or without with" should be --with or without--.

Column 20, Line 10, "preformed" should be --performed--.

Column 20, Line 17, "1982" should be --1992--.

Column 21, Line 1, "IFN- α " should be --IFN- α X--.

Column 22, Line 10, "interferon α 21b" should be --interferon- α 21b--.

Column 22, Line 13, "interferon- α 21b" should be -- interferon- α 21b--.

Column 22, Line 14, "interferon- α 2c." should be --interferon- α 2c--.

Column 23, Line 35, "polyakylene" should be --polyalkylene--.

Column 24, Table 1, Header, "(ng/ml)⁸" should be --(ng/ml)^a--.

Column 24, Table 1, Column 1, "IFN- α 21a" should be --IFN- α 21b--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,235,232 B2
APPLICATION NO. : 10/615723
DATED : June 26, 2007
INVENTOR(S) : Zoon et al.

Page 2 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 24, Table 1, Legend, “¹²⁸I-IFN-α2b” should be --¹²⁵I-IFN- α2b--.

Column 25, Table 1, Column 2, “NID” should be --N/D--.

In the Sequence Listing:
SEQ ID NOS: 43 and 44
Sequence Listing:

Col. 59 should read

<210> SEQ ID NO 43
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide
<220> FEATURE:
<221> NAME/KEY: misc feature
<222> LOCATION: (5)..(5)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
<220> FEATURE:
<221> NAME/KEY: misc feature
<222> LOCATION: (9)..(9)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 43

Leu Asp Lys Phe Xaa Thr Glu Leu Xaa Gln Gln Leu Asn Asp
1 5 10

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,235,232 B2
APPLICATION NO. : 10/615723
DATED : June 26, 2007
INVENTOR(S) : Zoon et al.

Page 3 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 59 should read

<210> SEQ ID NO 44
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5)..(5)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9)..(9)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 44

Leu Glu Lys Phe Xaa Thr Glu Leu Xaa Gln Gln Leu Asn Asp
1 5 10

Column 59, Line 44, “interferon α ” should be --interferon- α --.

Column 59, Line 64 to Column 60, Line 19, “wherein the second amino acid sequence consists of residues wherein the second amino acid sequence consists of residues 76-81” should be --wherein the second amino acid sequence consists of residues 76-81--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,235,232 B2
APPLICATION NO. : 10/615723
DATED : June 26, 2007
INVENTOR(S) : Zoon et al.


Page 4 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 60, Line 37, "wherein the second amino acid sequence consists of residues wherein the second amino acid sequence consists of 76-81" should be --wherein the second amino acid sequence consists of 76-81--.

Signed and Sealed this

Twenty-ninth Day of December, 2009

A handwritten signature in black ink, reading "David J. Kappos". The signature is written in a cursive, flowing style with a large initial 'D' and a stylized 'K'.

David J. Kappos
Director of the United States Patent and Trademark Office